"Immunotherapy has transformed the treatment of cancer with the body's own immune system being used to combat tumors. The session "Immunotherapy Response" addresses the question of why some patients respond well to these treatments while others do not show much or any benefit.".
Immunotherapy response is based on several parameters such as tumor genetics, immune cell infiltration, tumor microenvironment, and immune checkpoint expression such as PD-1/PD-L1. Predictive biomarkers allow clinicians to choose patients who would be most benefited by the immune-based therapies. This session will delve into ongoing research in immune profiling, cytokine signaling, and interaction between tumor and immune that dictates the therapy response.
Some of the strategies to maximize immunotherapy benefit are combination therapies with targeted agents, chemotherapy, or radiation to ready the immune system for a more potent assault on cancer cells. Elucidation of resistance and immune evasion mechanisms is also important to maximize the efficacy and durability of treatment.
Participants will learn about clinical and molecular determinants influencing response to immunotherapy, new predictive methods, and new ways to maximize patient benefit. This session highlights the significance of patient-specific strategies, therapy guided by biomarkers, and ongoing research toward ensuring the best potential for immunotherapy in the treatment of cancer, bringing new hope to cancer patients globally.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
